Abatacept (Orencia) for Rheumatoid Arthritis
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Abatacept (Orencia) for Rheumatoid Arthritis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1229
Article Code: 1229a
Date: February 27, 2006
Volume: 48
Pages: 17-18
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1229
Article Code: 1229a
Date: February 27, 2006
Volume: 48
Pages: 17-18
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)